Eficácia e segurança clínica do Estetrol: evidências terapêuticas de um estrogénio inovador
Abstract Estetrol (E4) is a native fetal estrogen with a distinct pharmacological profile, acting preferentially on alpha estrogen receptors. Estetrol (15 mg) in combination with drospirenone (3 mg) has been recently approved for contraception. The advantage of hormonal combined contraception with estetrol is demonstrated by neutral impact on hemostatic factors, decreased modulation on lipidic parameters which creates a unique safety profile that emphasizes the utility of E4 in clinical practice. Besides, the E4 use for the treatment of menopause related symptoms and for breast and prostate cancer control has been extensively studied.
Saved in:
| Main Authors: | , , , , , , |
|---|---|
| Format: | Digital revista |
| Language: | Portuguese |
| Published: |
Euromédice, Edições Médicas Lda.
2021
|
| Online Access: | http://scielo.pt/scielo.php?script=sci_arttext&pid=S1646-58302021000200161 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| Summary: | Abstract Estetrol (E4) is a native fetal estrogen with a distinct pharmacological profile, acting preferentially on alpha estrogen receptors. Estetrol (15 mg) in combination with drospirenone (3 mg) has been recently approved for contraception. The advantage of hormonal combined contraception with estetrol is demonstrated by neutral impact on hemostatic factors, decreased modulation on lipidic parameters which creates a unique safety profile that emphasizes the utility of E4 in clinical practice. Besides, the E4 use for the treatment of menopause related symptoms and for breast and prostate cancer control has been extensively studied. |
|---|